PROBLEM TO BE SOLVED: To provide a compound for treatment of Hepatitis C in combination with one or more additional Hepatitis C therapeutic agents, such as caspase inhibitor, cyclophilin inhibitor, metabolic pathway inhibitor, interferon.SOLUTION: According to the present invention, there is provided a compound exemplified by the following formula or a pharmaceutically acceptable salt thereof. According to the present invention, there is also provided a pharmaceutical composition comprising the compound in combination with one or more additional Hepatitis C therapeutic agents selected from an HCV NS2 protease inhibitor, an HCV NS3/4A protease inhibitor, an HCV NS3 helicase inhibitor, an HCV NS4B replication factor inhibitor, an HCV NS5B polymerase inhibitor, an HCV entry inhibitor, an HCV internal ribosome entry site inhibitor, a microsomal triglyceride transfer protein inhibitor, an α-glucosidase inhibitor, a caspase inhibitor, a cyclophilin inhibitor, an immunomodulator, a metabolic pathway inhibitor, an interferon, and a nucleoside； and a pharmaceutically acceptable excipient.SELECTED DRAWING: None【課題】カスパーゼ阻害剤、シクロフィリン阻害剤、代謝経路阻害剤、インターフェロン等の1種以上のC型肝炎治療剤と組み合わせるC型肝炎の治療のための化合物の提供。【解決手段】下式で例示される化合物又はその薬学的に許容される塩。前記化合物と、ＨＣＶ ＮＳ２プロテアーゼ阻害剤、ＨＣＶ ＮＳ３／４Ａプロテアーゼ阻害剤、ＨＣＶ ＮＳ３ヘリカーゼ阻害剤、ＨＣＶ ＮＳ４Ｂ複製因子阻害剤、ＨＣＶ ＮＳ５Ｂポリメラーゼ阻害剤、ＨＣＶ侵入阻害剤、ＨＣＶ内部リボソーム進入部位阻害剤、ミクロソームトリグリセリド輸送タンパク質阻害剤、α－グルコシダーゼ阻害剤、カスパーゼ阻害剤、シクロフィリン阻害剤、免疫モジュレーター、代謝経路阻害剤、インターフェロン、及びヌクレオシド類似体から選択される１種以上の追加のＣ型肝炎治療剤と、薬学的に許容される賦形剤と、を組み合わせて含む医薬組成物。【選択図】なし
